drugset / Trial / NCT07001150
Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
Phase 2
Recruiting
50 enrolled
Tanta University
Dr. Raed Ahmed Abdel-Maboud,Lecturer of neurology,Faculty of Medicine,Tanta University · collabProf. Sahar Kamal Hegazy,Head of Clinical Pharmacy Department,Faculty of Pharmacy,Tanta University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.
Timeline
- Start
- 2025-05-10
- Primary completion
- 2026-05-30
- Completion
- 2026-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Silymarin | Traditional medicine (herbal / TCM) | 140 mg | — |
| Comparator | Carbidopa | Unknown | — | — |
| Comparator | Levodopa | Small molecule | — | — |